Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EryDex
- Development stage
- Discontinued
- Lead developer
- Quince Therapeutics
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
**EryDex** is an investigational, autologous red-blood-cell delivery formulation of **dexamethasone sodium phosphate**. The EryDex System loads dexamethasone sodium phosphate ex vivo into a patient's own erythrocytes, which are then reinfused intravenously to provide sustained systemic release of dexamethasone over approximately one month. Dexamethasone is a glucocorticoid receptor agonist with anti-inflammatory and immunomodulatory transcriptional effects. EryDex was developed by EryDel and subsequently advanced by Quince Therapeutics, principally for neurological manifestations of ataxia-telangiectasia. Following failure of the pivotal Phase 3 NEAT trial to meet its primary and key secondary endpoints, Quince announced on January 29, 2026 that it would cease clinical development of eDSP, the name then used for EryDex. ([quincetx.com](https://quincetx.com/pipeline/))
- Brand names
- EryDex
- Other names
- eDSPdex-21-Pdex21-Pdex 21-Pdexamethasone sodium phosphate encapsulated in autologous erythrocytes
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on EryDex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EryDex.